Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 18/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592258 | 0.88 | ADORA2A (0.39) | — | |
| SCHEMBL21591468 | 0.86 | FGFR1 (0.31) | — | |
| SCHEMBL21591500 | 0.73 | HDAC3 (0.41) | — | |
| SCHEMBL31361801 | 0.73 | HDAC3 (0.41) | — | |
| SCHEMBL21592263 | 0.71 | POLB (0.34) | — | |
| SCHEMBL21592266 | 0.67 | ALDH1A1 (0.41) | — | |
| SCHEMBL21591449 | 0.66 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL21591439 | 0.66 | CYP11B1 (0.37) | — | |
| SCHEMBL27670855 | 0.61 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL22017431 | 0.60 | HPRT1 (0.68) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| EP-3807264-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | HPRT1 379/4885PNP 1020/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | HPRT1 379/4885PNP 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.